Healthcare Sector Declines 1.2%, Moderna Falls 7.2% Amidst Market Weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Source: NASDAQ.COM
- Healthcare Sector Decline: As of midday Friday, the healthcare sector is down 1.2%, with Moderna Inc (MRNA) and Insulet Corp (PODD) showing losses of 7.2% and 4.5%, respectively, indicating overall sector weakness that may impact investor confidence.
- ETF Performance Analysis: The Health Care Select Sector SPDR ETF (XLV), which tracks the healthcare sector, is down 0.8% on the day but up 1.48% year-to-date, suggesting that despite short-term volatility, the long-term trend remains positive, potentially attracting investor interest.
- Moderna Year-to-Date Performance: Moderna Inc has risen 63.22% year-to-date, and despite the recent pullback, its strong annual performance may attract long-term investors, especially in the context of ongoing vaccine demand.
- Utilities Sector Performance: The utilities sector is also underperforming, down 1.0%, with AES Corp (AES) and Exelon Corp (EXC) showing declines of 2.7% and 2.0%, respectively, reflecting a weakening demand for defensive stocks in the current market environment.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 29.36 USD with a low forecast of 17.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
1 Buy
14 Hold
4 Sell
Hold
Current: 45.300
Low
17.00
Averages
29.36
High
63.00
Current: 45.300
Low
17.00
Averages
29.36
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna Stock Rises 58% in 2026, Signaling New Opportunities
- Stock Rebound: Moderna's stock has surged 58% in 2026, indicating a potential start of a sustained bull run after several years of stagnant revenue growth.
- Clinical Trial Progress: The intismeran autogene, in combination with Merck's Keytruda, demonstrated a 49% reduction in disease recurrence or death in advanced melanoma patients, highlighting its potential in cancer treatment.
- Product Portfolio Expansion: In addition to intismeran autogene, Moderna is conducting up to eight phase 2 or phase 3 clinical trials, and meaningful progress could significantly enhance the company's market competitiveness and product diversity.
- Long-Term Investment Value: Despite a substantial decline in stock price over the past three years, Moderna's strong performance in 2026 and future clinical and regulatory advancements make it a compelling consideration for long-term investors.
Continue Reading
Moderna's Drug Candidate Shows Strong Clinical Trial Results
- Clinical Trial Success: Moderna's intismeran autogene shows a 49% reduction in disease recurrence or death when combined with Merck's Keytruda, indicating significant potential in treating advanced melanoma and possibly opening new revenue streams for the company.
- Market Recovery: Moderna's stock has surged 58% in 2026, reflecting renewed investor confidence and potentially signaling the start of a sustained bull run for the company's shares.
- Product Line Expansion: With eight ongoing phase 2 or phase 3 studies, Moderna could significantly enhance its market competitiveness and diversify its product offerings if it achieves breakthroughs in cancer treatment.
- Collaborative Opportunities: While Moderna will share profits with Merck for intismeran autogene, the therapy's potential to become a blockbuster, combined with Keytruda's established market position, could yield substantial commercial opportunities for the company.
Continue Reading